{"result": {"id": "0bdf6beb-205e-40ba-a36c-107bf7f7ea34", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>INSIGHT<|>EVENT<|>Intervention as a Goal in Hypertension Treatment study comparing long-acting calcium-channel blockers and diuretics>  \n##  \n(\"entity\"<|>LANCET<|>ORGANIZATION<|>Medical journal publishing hypertension research studies>  \n##  \n(\"entity\"<|>HYPERTENSION<|>ORGANIZATION<|>Journal publishing cardiovascular research including the HONEST study>  \n##  \n(\"entity\"<|>AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION<|>ORGANIZATION<|>Published expert consensus on hypertension in the elderly>  \n##  \n(\"entity\"<|>CHINESE SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>Published Chinese guidelines on heart failure diagnosis/treatment>  \n##  \n(\"entity\"<|>FRENCH SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>Parent organization of French Society of Hypertension>  \n##  \n(\"entity\"<|>BROWN MJ<|>PERSON<|>Researcher affiliated with INSIGHT hypertension study>  \n##  \n(\"entity\"<|>KARIO K<|>PERSON<|>Researcher leading HONEST blood pressure study>  \n##  \n(\"entity\"<|>WEBER MA<|>PERSON<|>Researcher involved in VALUE Trial>  \n##  \n(\"entity\"<|>WRIGHT JT<|>PERSON<|>SPRINT Research Group lead investigator>  \n##  \n(\"relationship\"<|>INSIGHT<|>LANCET<|>INSIGHT study results published in The Lancet<|>8>  \n##  \n(\"relationship\"<|>HONEST<|>HYPERTENSION<|>HONEST study published in Hypertension journal<|>8>  \n##  \n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION<|>FRENCH SOCIETY OF HYPERTENSION<|>Both produce hypertension treatment guidelines<|>5>  \n##  \n(\"relationship\"<|>CHINESE SOCIETY OF CARDIOLOGY<|>FRENCH SOCIETY OF CARDIOLOGY<|>Both national cardiology organizations publishing guidelines<|>4>  \n##  \n(\"relationship\"<|>BROWN MJ<|>INSIGHT<|>Brown MJ was an investigator in INSIGHT study<|>7>  \n##  \n(\"relationship\"<|>KARIO K<|>HONEST<|>Kario K led the HONEST study<|>9>  \n##  \n(\"relationship\"<|>WEBER MA<|>VALUE TRIAL<|>Weber MA contributed to VALUE Trial research<|>7>  \n##  \n(\"relationship\"<|>WRIGHT JT<|>SPRINT RESEARCH GROUP<|>Wright JT led the SPRINT trial<|>9>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166395, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 637, "prompt_tokens": 3366, "total_tokens": 4003, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2880}, "prompt_cache_hit_tokens": 2880, "prompt_cache_miss_tokens": 486}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 003\n[14]     Brown    MJ,Palmer   CR,Castaigne    A,et    al.Morbidity   and mortality  in  patients  randomised  to  double-blind  treatment  with a long-acting calcium-channel blocker or diuretic in the  International Nifedipine GITS study:Intervention as a Goal in Hypertension      Treatment      (INSIGHT)[J].Lancet,2000,356 (9227):366-372.DOI:10.1016/S0140-6736(00)02527-7.\n[15]      Kario  K,Saito  I,Kushiro  T,et  al.Home  blood  pressure  and cardiovascular  outcomes  in  patients  during  antihypertensive therapy:primary results of HONEST,a large-scale prospective, real-world   observational   study[J].Hypertension,2014,64(5): 989-996.DOI:10.1161/HYPERTENSIONAHA.114.04262.\n[16]     Weber    MA,Julius     S,Kjeldsen    SE,et    al.Blood    pressure dependent   and   independent   effects   of   antihypertensive treatment  on  clinical  events  in  the  VALUE  Trial[J].Lancet, 2004,363(9426):2049-2051.DOI:10.1016/S0140-6736(04)\n16456-8.\n[17]  王文，马丽媛，刘明波，等.初始低剂量氨氯地平加替米沙坦\n或复方阿米洛利联合治疗对高血压患者血压控制率影响 的阶段报告[J].中华心血管病杂志，2009,25(8):701-707.DOI: 10.3760/cma.j.issn.0253-3758.2009.08.007.\n[18]     Franklin    SS,Lopez    VA,Wong    ND,et     al.Single    versus combined    blood    pressure     components    and     risk    for\n\n\n\ncardiovascular   disease:the   Framingham   Heart    Study   [J].\nCirculation,2009,119(2):243-250.                DOI:10.1161        /\nCIRCULATIONAHA.108.797936.\n[19]       Zheng   L,Li   J,Sun  Z,et  al.Relationship  of  Blood  Pressure With     Mortality     and     Cardiovascular     Events     Among Hypertensive  Patients  aged>/=60  years  in  Rural  Areas  of China:A     Strobe-Compliant     Study[J].Medicine(Baltimore), 2015,94(39):e1551.DOI:10.1097/MD.0000000000001551.\n[20]       Aronow     WS,Fleg     JL,et     al.ACCF/AHA     2011     expert consensus document on hypertension in the elderly:a report of the American College of Cardiology Foundation Task Force on Clinical   Expert   Consensus   Documents[J].Circulation,2011, 123(21):2434-2506.DOI:10.1161/CIR.0b013e31821daaf6.\n[21]       SPRINT  Research  Group,Wright  JT,Williamson  JD,et  al.A Randomized Trial of Intensive versus Standard Blood-Pressure Control[J].N    Engl     J     Med,2015,373(22):2103-2116.DOI:\n10.1056/NEJMx170008.\n[22]   中华医学会心血管病学分会，中华心血管病杂志编辑委员\n会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病 杂志，2014(2):98-122.DOI:10.3760/cma.j.issn.0253-3758.     2014.02.004.\n[23]     Leenen  FH,Nwachuku  CE,Black  HR,et  al.Clinical  events  in   high-risk hypertensive patients randomly assigned to calcium channel    blocker    versus     angiotensin-converting    enzyme inhibitor in the antihypertensive and lipid-lowering treatment\n\n\n\nto   prevent    heart    attack   trial[J].Hypertension,2006,48(3): 374-384.DOI:10.1161/01.HYP.0000231662.77359.de.\n[24]     Denolle    T,Chamontin    B,Doll    G,et    al.Management    of resistant  hypertension:expert  consensus  statement  from  the French  Society  of  Hypertension,an  affiliate  of  the  French Society   of   Cardiology[J].J    Hum   Hypertens,2016,30(11): 657-663.DOI:10.1038/jhh.2015.122.\n[25]      Oliveras  A,Armario   P,Clara  A,et   al.Spironolactone  versus sympathetic    renal    denervation    to    treat    true    resistant hypertension:results from the DENERV\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>INTERNATIONAL NIFEDIPINE GITS STUDY<|>EVENT<|>A study comparing long-acting calcium-channel blockers and diuretics in hypertension treatment>  \n##  \n(\"entity\"<|>HONEST<|>EVENT<|>A large-scale prospective observational study on home blood pressure and cardiovascular outcomes during antihypertensive therapy>  \n##  \n(\"entity\"<|>VALUE TRIAL<|>EVENT<|>A trial investigating blood pressure-dependent and independent effects of antihypertensive treatment on clinical events>  \n##  \n(\"entity\"<|>FRAMINGHAM HEART STUDY<|>EVENT<|>A study analyzing single versus combined blood pressure components and their risk for cardiovascular disease>  \n##  \n(\"entity\"<|>SPRINT RESEARCH GROUP<|>ORGANIZATION<|>Conducted a randomized trial comparing intensive versus standard blood-pressure control>  \n##  \n(\"entity\"<|>FRENCH SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>An affiliate of the French Society of Cardiology, issued expert consensus on resistant hypertension>  \n##  \n(\"entity\"<|>DENERV<|>EVENT<|>A study comparing spironolactone and sympathetic renal denervation for resistant hypertension>  \n##  \n(\"relationship\"<|>INTERNATIONAL NIFEDIPINE GITS STUDY<|>HONEST<|>Both are studies focused on hypertension treatment and outcomes<|>4>  \n##  \n(\"relationship\"<|>VALUE TRIAL<|>FRAMINGHAM HEART STUDY<|>Both investigate blood pressure effects on cardiovascular events<|>5>  \n##  \n(\"relationship\"<|>SPRINT RESEARCH GROUP<|>FRENCH SOCIETY OF HYPERTENSION<|>Both organizations contribute to hypertension research and guidelines<|>3>  \n##  \n(\"relationship\"<|>DENERV<|>FRENCH SOCIETY OF HYPERTENSION<|>DENERV study aligns with the Society's focus on resistant hypertension<|>6>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_8297d0e1fdbc99477c8fadaa43d8a33d244812ab9fe960a92b511297239fecf1_v2"}